Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Drug Manufacturers — General

Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products for humans and animals. The Company products are sold in countries around the world. Eli Lilly products include neuroscience, endocrine, anti-infectives, cardiovascular agents, oncology, and animal health products.
Website: lilly.com



Growth: Good revenue growth rate 53.9%, there is acceleration compared to average historical growth rates 28.1%. The revenue growth dynamics is moderately stable Site traffic for the last 3 months showed a change of -19.1%

Profitability: LTM EBITDA margin is positive, +42.0%. On average the margin is improving unsteadily. Gross margin is high, +82.9%. In the last quarter the company did not beat the estimated EPS, -6.4%. The company was ahead of estimated EPS in 60% of quarters (showing a gain of +$0.02 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.6%. Free cash flow yield -0.5% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 230.0% higher than minimum and 7.7% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued 5.4x by EV / Sales multiple , the company can be 66.7% overvalued

Insiders: For the last 3 months insiders sold company shares on $77 324.8 mln (-0.168% of cap.)

Key Financials (Download financials)

Ticker: LLY
Share price, USD:  (-1.9%)1025
year average price 857.05  


year start price 872.97 2025-02-12

min close price 625.65 2025-08-08

max close price 1109.94 2025-11-25

current price 1025.00 2026-02-11
Common stocks: 900 605 000

Dividend Yield:  0.6%
FCF Yield LTM: -0.5%
EV / LTM EBITDA: 38.3x
EV / EBITDA annualized: 30.5x
Last revenue growth (y/y):  +53.9%
Last growth of EBITDA (y/y):  > +200.0%
Historical revenue growth:  +28.1%
Historical growth of EBITDA:  +59.8%
EV / Sales: 16.1x
Margin (EBITDA LTM / Revenue): 42.0%
Fundamental value created in LTM:
Market Cap ($m): 923 120
Net Debt ($m): 32 651
EV (Enterprise Value): 955 771
Price to Book: 38.8x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2026-02-07fool.com

3 Things Investors Need to Know About the Healthcare Sector in 2026

2026-02-07reuters.com

Weight-loss drugs to compete on biggest stage with Super Bowl ads

2026-02-06marketbeat.com

Eli Lilly Booms, Then Busts: Stellar Guidance vs Hims Undercut

2026-02-05seekingalpha.com

Eli Lilly: Positives Outweigh The Concerns

2026-02-05marketbeat.com

The Metabolic Split: Why Eli Lilly Soars as Novo Stumbles

2026-02-04seekingalpha.com

Eli Lilly and Company (LLY) Q4 2025 Earnings Call Transcript

2026-02-04investopedia.com

Eli Lilly Stock Soars While Novo Nordisk Sinks—Why the Weight-Loss Leaders Are Headed in Opposite Directions

2026-02-04zacks.com

Lilly Stock Jumps After Q4 Earnings Beat and Strong 2026 Guidance

2026-02-04schaeffersresearch.com

Eli Lilly Stock Eyes Best Day Since October After Quarterly Beat

2026-02-04proactiveinvestors.com

Eli Lilly shares soar after Q4 beat, strong forecast on weight-loss drugs
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2025 q4 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-12-31 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol LLY LLY LLY LLY LLY LLY LLY LLY LLY LLY LLY LLY LLY LLY LLY
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 59 478 59 478 59 478 59 478 59 478 59 478 59 478 59 478 59 478 59 478 59 478 59 478 59 478 59 478 59 478
filingDate 2025-12-31 2025-02-19 2024-02-21 2023-02-22 2022-02-23 2021-02-17
acceptedDate 2025-12-30 19:00:00 2025-10-30 11:15:28 2025-08-07 09:59:55 2025-02-19 10:10:59 2024-10-30 11:54:10 2024-08-08 11:28:54 2024-04-30 12:04:51 2024-02-21 11:44:37 2023-11-02 11:21:53 2023-08-08 13:23:19 2023-04-27 11:56:56 2023-02-22 10:26:53 2022-11-01 11:16:21 2022-02-23 11:00:57 2021-02-17 10:59:12
fiscalYear 2025 2024 2023 2022 2021 2020
period FY Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
revenue 65 179M 17 601M 15 558M 45 043M 11 439M 11 303M 8 768M 34 124M 9 499M 8 312M 6 960M 28 541M 6 942M 28 318M 24 540M
costOfRevenue 10 564M 3 008M 2 448M 8 418M 2 171M 2 170M 1 534M 7 082M 1 860M 1 807M 1 627M 6 630M 1 579M 7 313M 5 483M
grossProfit 54 615M 14 593M 13 110M 36 624M 9 268M 9 133M 7 234M 27 042M 7 639M 6 505M 5 333M 21 912M 5 363M 21 006M 19 057M
researchAndDevelopmentExpenses 13 338M 4 121M 3 336M 10 991M 2 734M 2 711M 2 523M 9 313M 2 409M 2 357M 1 985M 7 191M 1 803M 6 931M 5 976M
generalAndAdministrativeExpenses 11 094M 2 741M 2 648M 8 132M 2 100M 2 003M 1 836M 6 941M 1 804M 1 925M 1 749M 6 068M 0 6 142M 5 869M
sellingAndMarketingExpenses 0 0 0 0 0 114M 116M 0 0 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 11 094M 2 741M 2 648M 8 132M 2 100M 2 117M 1 952M 6 941M 1 804M 1 925M 1 749M 6 068M 1 614M 6 142M 5 869M
otherExpenses 488M 0 0 0 0 -8M -139M 0 53M 38M 104M 0 0 0 0
operatingExpenses 24 919M 6 862M 5 984M 19 123M 4 834M 4 829M 4 614M 16 255M 4 213M 4 282M 3 734M 13 258M 3 417M 13 073M 11 846M
costAndExpenses 35 483M 9 870M 8 432M 27 541M 7 005M 6 999M 6 149M 23 337M 6 073M 6 089M 5 361M 19 888M 4 996M 20 385M 17 329M
netInterestIncome -642M -605M -312M -269M -314M -327M
interestIncome 153M 65M 40M 175M 48M 37M 46M 174M 49M 46M 34M 63M 20M 25M 33M
interestExpense 795M 180M 249M 781M 193M 184M 134M 486M 125M 120M 103M 332M 82M 340M 360M
depreciationAndAmortization 1 564M 470M 479M 1 767M 467M 414M 401M 1 527M 5 950M 366M 210M 1 523M 363M 1 548M 1 324M
ebitda 27 937M 7 882M 7 504M 15 228M 2 248M 4 115M 3 211M 8 568M 6 401M 2 320M 1 704M 8 661M 2 010M 8 043M 8 913M
ebit 26 373M 13 461M 7 041M 7 138M 6 495M 7 590M
nonOperatingIncomeExcludingInterest 3 323M 4 041M 3 747M 1 515M 1 438M -379M
operatingIncome 29 696M 7 730M 7 126M 17 502M 4 434M 4 304M 2 620M 10 787M 450M 2 126M 1 494M 8 653M 1 647M 7 933M 7 211M
totalOtherIncomeExpensesNet -3 965M -498M -350M -4 821M -2 846M -787M -83M -4 233M -2 923M -60M 36M -1 847M -82M -1 778M 19M
incomeBeforeTax 25 730M 7 232M 6 776M 12 680M 1 588M 3 517M 2 536M 6 555M 427M 2 089M 1 530M 6 806M 1 566M 6 156M 7 230M
incomeTaxExpense 5 092M 1 650M 1 116M 2 090M 618M 550M 293M 1 314M 485M 326M 185M 562M 114M 574M 1 036M
netIncomeFromContinuingOperations 20 638M 10 590M 5 240M 6 245M 5 582M 6 194M
netIncomeFromDiscontinuedOperations 0 0 0 0 0 0
otherAdjustmentsToNetIncome 0 0 0 0 0 0
netIncome 20 638M 5 583M 5 661M 10 590M 970M 2 967M 2 243M 5 240M -57M 1 763M 1 345M 6 245M 1 452M 5 582M 6 194M
netIncomeDeductions 0 0 0 0 0 0
bottomLineNetIncome 20 638M 10 590M 5 240M 6 245M 5 582M 6 194M
eps 15.59 6.22 6.3 11.76 1.08 3.29 2.49 5.83 -0.064 1.96 1.49 6.57 1.61 5.85 6.47
epsDiluted 22.95 11.71 5.8 6.57 5.85 6.47
weightedAverageShsOut 898M 897M 898M 901M 901M 901M 901M 899M 900M 900M 903M 950M 901M 954M 957M
weightedAverageShsOutDil 898M 899M 900M 904M 905M 904M 904M 903M 900M 903M 903M 950M 904M 954M 957M
fillingDate 2025-10-30 2025-08-07 2024-10-30 2024-08-08 2024-04-30 2023-11-02 2023-08-08 2023-04-27 2022-11-01
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
grossProfitRatio 0.829 0.843 0.81 0.808 0.825 0.804 0.783 0.766 0.773
ebitdaratio 0.448 0.482 0.197 0.417 0.366 0.674 0.279 0.245 0.29
operatingIncomeRatio 0.439 0.458 0.388 0.381 0.299 0.047 0.256 0.215 0.237
incomeBeforeTaxRatio 0.411 0.436 0.139 0.311 0.289 0.045 0.251 0.22 0.226
netIncomeRatio 0.317 0.364 0.085 0.263 0.256 -0.006 0.212 0.193 0.209
epsdiluted 6.21 6.29 1.07 3.28 2.48 -0.064 1.95 1.49 1.61
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link

Balance Sheet Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol LLY LLY LLY LLY LLY LLY LLY LLY LLY LLY LLY LLY LLY LLY
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 59 478 59 478 59 478 59 478 59 478 59 478 59 478 59 478 59 478 59 478 59 478 59 478 59 478 59 478
fillingDate 2025-10-30 2025-08-07 2024-10-30 2024-08-08 2024-04-30 2023-11-02 2023-08-08 2023-04-27 2022-11-01
acceptedDate 2025-10-30 11:15:28 2025-08-07 09:59:55 2025-02-19 10:10:59 2024-10-30 11:54:10 2024-08-08 11:28:54 2024-04-30 12:04:51 2024-02-21 11:44:37 2023-11-02 11:21:53 2023-08-08 13:23:19 2023-04-27 11:56:56 2023-02-22 10:26:53 2022-11-01 11:16:21 2022-02-23 11:00:57 2021-02-17 10:59:12
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
cashAndCashEquivalents 9 792M 3 376M 3 268M 3 369M 3 224M 2 460M 2 819M 2 381M 2 695M 3 546M 2 067M 2 617M 3 819M 3 657M
shortTermInvestments 122M 170M 155M 149M 140M 126M 109M 113M 135M 123M 145M 125M 90M 24M
cashAndShortTermInvestments 9 914M 3 546M 3 423M 3 518M 3 364M 2 586M 2 928M 2 494M 2 829M 3 669M 2 212M 2 742M 3 909M 3 681M
netReceivables 19 457M 17 206M 13 275M 12 052M 13 079M 10 014M 11 336M 10 364M 9 171M 9 022M 8 559M 8 325M 8 127M 6 929M
inventory 12 180M 11 014M 7 589M 7 460M 6 482M 6 102M 5 773M 4 901M 4 799M 4 545M 4 310M 3 831M 3 886M 3 980M
otherCurrentAssets 20 520M 18 089M 111M 8 385M 7 280M 139M 150M 5 248M 4 532M 3 575M 7M 2 742M 0 0
totalCurrentAssets 62 071M 49 854M 32 740M 31 415M 30 204M 25 189M 25 727M 23 007M 21 332M 20 811M 18 035M 17 640M 18 452M 17 462M
propertyPlantEquipmentNet 22 316M 20 530M 17 102M 16 172M 14 829M 13 624M 12 914M 11 863M 11 277M 10 546M 10 144M 9 311M 8 985M 8 682M
goodwill 5 898M 5 771M 5 770M 5 768M 5 768M 4 940M 4 940M 4 085M 4 079M 4 073M 4 073M 3 892M 3 892M 3 767M
intangibleAssets 6 447M 5 908M 6 166M 6 537M 6 636M 6 762M 6 907M 6 782M 6 904M 7 087M 7 207M 7 124M 7 692M 7 450M
goodwillAndIntangibleAssets 12 345M 11 679M 11 937M 12 306M 12 404M 11 702M 11 846M 10 867M 10 982M 11 160M 11 280M 11 016M 11 584M 11 217M
longTermInvestments 2 808M 3 207M 3 216M 3 200M 2 925M 3 087M 3 052M 2 692M 2 745M 2 750M 2 902M 2 575M 3 213M 2 967M
taxAssets 8 963M 9 427M 8 001M 7 392M 6 655M 5 634M 5 477M 4 575M 3 806M 3 407M 2 793M 2 384M 2 489M 2 830M
otherNonCurrentAssets 6 432M 6 225M 5 720M 5 122M 4 857M 4 708M 4 990M 4 912M 4 672M 4 488M 4 337M 4 536M 4 083M 3 475M
totalNonCurrentAssets 52 864M 51 069M 45 975M 44 192M 41 671M 38 755M 38 279M 34 909M 33 482M 32 352M 31 455M 29 822M 30 354M 29 171M
otherAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalAssets 114 935M 100 923M 78 715M 75 607M 71 875M 63 944M 64 006M 57 916M 54 814M 53 163M 49 490M 47 462M 48 806M 46 633M
accountPayables 4 262M 4 076M 3 229M 2 887M 2 925M 2 474M 2 599M 2 435M 2 474M 2 016M 1 931M 1 683M 1 671M 1 607M
shortTermDebt 1 633M 5 724M 5 117M 2 074M 5 162M 1 652M 6 905M 2 245M 662M 3M 1 501M 1 745M 1 538M 9M
taxPayables 9 444M 6 958M 0 3 879M 3 497M 4 189M 3 849M 1 978M 1 234M 1 528M 475M 686M 127M 495M
deferredRevenue 0 0 0 0 3 497M 4 189M 0 1 978M 1 234M 0 0 0 0 0
otherCurrentLiabilities 24 801M 22 263M 7 145M 15 835M 15 538M 10 284M 16 140M 15 341M 14 545M 13 991M 3 905M 12 225M 10 683M 9 299M
totalCurrentLiabilities 40 141M 39 020M 28 377M 24 674M 27 121M 18 598M 27 293M 21 998M 18 915M 16 010M 17 138M 15 653M 15 053M 12 482M
longTermDebt 40 874M 34 180M 28 527M 29 045M 23 730M 24 560M 18 321M 17 924M 18 158M 18 881M 14 738M 14 144M 15 346M 16 587M
deferredRevenueNonCurrent 0 0 0 0 0 0 0 0 0 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 6 294M 0 0 0 0 0 0 0 0 0 87M 172M 1 734M 2 100M
otherNonCurrentLiabilities 3 777M 9 374M 7 540M 7 567M 7 388M 7 888M 7 529M 6 686M 6 591M 6 978M 6 751M 18 215M 7 518M 9 640M
totalNonCurrentLiabilities 50 944M 43 554M 36 067M 36 612M 31 118M 32 448M 25 849M 24 610M 24 750M 25 858M 21 576M 21 643M 24 599M 28 326M
otherLiabilities 0 0 0 0 0 0 0 0 0 0 0 0 0 0
capitalLeaseObligations 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalLiabilities 91 085M 82 574M 64 443M 61 286M 58 239M 51 046M 53 143M 46 608M 43 665M 41 868M 38 714M 37 296M 39 651M 40 808M
preferredStock 0 0 0 0 0 0 0 0 0 0 0 0 0 0
commonStock 591M 592M 592M 594M 594M 594M 594M 594M 594M 594M 594M 594M 596M 598M
retainedEarnings 22 252M 17 376M 13 545M 13 627M 13 178M 12 554M 10 312M 10 310M 10 369M 10 639M 10 043M 10 007M 8 959M 7 830M
accumulatedOtherComprehensiveIncomeLoss -3 206M -3 716M -4 322M -4 275M -4 379M -4 300M -4 327M -3 785M -3 789M -3 777M -3 845M -4 296M -4 343M -9 510M
othertotalStockholdersEquity 4 156M 4 021M 4 294M 4 168M 3 964M 4 102M 3 890M 3 735M 3 765M
totalStockholdersEquity 23 793M 18 273M 14 192M 14 240M 13 562M 12 812M 10 772M 11 220M 11 064M 11 190M 10 650M 10 070M 8 979M 5 642M
totalEquity 23 851M 18 349M 14 272M 14 321M 13 636M 12 897M 10 864M 11 307M 11 149M 11 190M 10 775M 10 070M 9 155M 5 825M
totalLiabilitiesAndStockholdersEquity 114 935M 100 923M 75 607M 71 875M 63 944M 57 916M 54 814M 53 163M 47 366M
minorityInterest 58M 76M 80M 81M 74M 85M 92M 87M 86M 105M 126M 0 176M 184M
totalLiabilitiesAndTotalEquity 114 935M 100 923M 78 715M 75 607M 71 875M 63 944M 64 006M 57 916M 54 814M 53 163M 49 490M 47 366M 48 806M 46 633M
totalInvestments 2 930M 3 378M 3 371M 3 350M 3 065M 3 213M 3 161M 2 805M 2 880M 2 874M 3 047M 2 699M 3 303M 2 991M
totalDebt 42 507M 39 904M 33 644M 31 120M 28 892M 26 211M 25 225M 20 168M 18 820M 18 884M 16 239M 15 888M 16 885M 16 595M
netDebt 32 715M 36 528M 30 376M 27 751M 25 668M 23 751M 22 407M 17 788M 16 126M 15 338M 14 172M 13 271M 13 066M 12 938M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-19 2024-02-21 2023-02-22 2022-02-23 2021-02-17
fiscalYear 2024 2023 2022 2021 2020
accountsReceivables 11 006M 9 091M 6 896M 6 673M 5 875M
otherReceivables 2 270M 2 246M 1 663M 1 454M 1 054M
prepaids 8 341M 5 541M 2 947M 2 531M 2 872M
totalPayables 4 575M 2 599M 2 948M 1 798M 2 102M
otherPayables 1 346M 0 1 017M 127M 495M
accruedExpenses 11 539M 1 650M 8 784M 1 034M 1 073M
capitalLeaseObligationsCurrent 0 0 0 0 0
capitalLeaseObligationsNonCurrent 0 0 0 0 0
treasuryStock -50M -44M -51M -53M -56M
additionalPaidInCapital 7 439M 7 250M 6 921M 6 833M 6 779M
otherTotalStockholdersEquity -3 013M -3 013M -3 013M -3 013M 0

Cash Flow Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol LLY LLY LLY LLY LLY LLY LLY LLY LLY LLY LLY LLY LLY LLY
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 59 478 59 478 59 478 59 478 59 478 59 478 59 478 59 478 59 478 59 478 59 478 59 478 59 478 59 478
fillingDate 2025-10-30 2025-08-07 2024-10-30 2024-08-08 2024-04-30 2023-11-02 2023-08-08 2023-04-27 2022-11-01
acceptedDate 2025-10-30 11:15:28 2025-08-07 09:59:55 2025-02-19 10:10:59 2024-10-30 11:54:10 2024-08-08 11:28:54 2024-04-30 12:04:51 2024-02-21 11:44:37 2023-11-02 11:21:53 2023-08-08 13:23:19 2023-04-27 11:56:56 2023-02-22 10:26:53 2022-11-01 11:16:21 2022-02-23 11:00:57 2021-02-17 10:59:12
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
netIncome 5 583M 5 661M 10 590M 970M 2 967M 2 243M 5 240M -57M 1 763M 1 345M 6 245M 1 452M 5 582M 6 194M
depreciationAndAmortization 470M 479M 1 767M 467M 414M 401M 1 527M 411M 366M 362M 1 523M 363M 1 548M 1 324M
deferredIncomeTax 501M -1 069M -2 683M -430M -1 008M -279M -2 341M -844M -431M -559M -2 185M -1 071M -802M -135M
stockBasedCompensation 151M 185M 646M 133M 211M 159M 629M 216M 162M 131M 371M 85M 343M 308M
changeInWorkingCapital 5 627M -2 263M -5 385M -10M -1 399M -1 751M -3 055M 793M -840M 164M -800 000 939M -1 013M -747M
accountsReceivables 0 0 -2 155M 0 0 0 -2 451M 0 0 0 -300M 0 -1 278M -1 350M
inventory 0 0 -2 507M 0 0 0 -1 425M 0 0 0 -600M 0 -236M -533M
accountsPayables 0 0 2 609M 0 0 0 4 274M 0 0 0 1 332M 0 -1 014M 1 271M
otherWorkingCapital 5 627M -2 263M -3 331M -10M -1 399M -1 751M -3 453M 793M 0 0 -433M 0 1 515M -135M
otherNonCashItems -3 496M 94M 3 884M 2 581M 1 320M 409M 2 240M 1 671M -388M 288M 1 633M 417M 1 709M -444M
netCashProvidedByOperatingActivities 8 836M 3 087M 8 818M 3 712M 1 466M 1 166M 4 240M 2 190M 632M 1 731M 7 586M 2 185M 7 366M 6 500M
investmentsInPropertyPlantAndEquipment -2 088M -1 697M -5 058M -1 173M -1 403M -986M -3 448M -4 001M -836M -904M -1 854M -620M -1 310M -2 029M
acquisitionsNet -549M 0 -948M 0 -948M 0 -1 044M -1 427M -98M 0 -327M 0 -747M -849M
purchasesOfInvestments -150M -171M -776M -295M -157M -142M -829M -151M -234M -169M -708M -255M -1 013M -370M
salesMaturitiesOfInvestments 556M 204M 523M 100M 214M 112M 700M 133M 155M 343M 464M 109M 847M 887M
otherInvestingActivites -752M -171M -2 637M 96M -65M 2 365M 555M 40M -160M
netCashUsedForInvestingActivites -2 983M -1 835M -4 005M -2 199M -1 178M -3 081M -459M -689M -923M
debtRepayment 2 615M 825M 1 875M 2 736M -1 248M -1 595M 0 0 0
commonStockIssued 0 0 0 0 0 0 0 0 0
commonStockRepurchased -708M -692M -2 500M -446M 0 0 -750M 0 0 -750M -1 500M 0 -1 250M -500M
dividendsPaid -1 345M -1 347M -1 171M -1 172M -1 169M -1 016M -1 018M -1 017M -882M
otherFinancingActivites -30M -30M -47M -8M -390M 3 183M -16M 2 180M -381M
netCashUsedProvidedByFinancingActivities 531M -1 245M 211M 1 556M -311M 572M -1 033M 412M -1 263M
effectOfForexChangesOnCash 32M 276M -297M 227M -60M -36M 169M 5M 9M 25M -168M -4M -206M 216M
netChangeInCash 6 416M 283M 450M 145M 763M -358M 752M -314M -851M 1 479M -1 752M -6M 161M 1 320M
cashAtEndOfPeriod 9 792M 3 376M 3 268M 3 369M 3 224M 2 460M 2 819M 2 381M 2 695M 3 546M 2 067M 2 617M 3 819M 3 657M
cashAtBeginningOfPeriod 3 376M 3 093M 2 819M 3 224M 2 460M 2 819M 2 067M 2 695M 3 546M 2 067M 3 819M 2 623M 3 657M 2 338M
operatingCashFlow 8 836M 3 087M 8 818M 3 712M 1 466M 1 166M 4 240M 2 190M 632M 1 731M 7 586M 2 185M 7 366M 6 500M
capitalExpenditure -224M -1 804M -8 404M -4 171M -1 403M -986M -7 392M -4 001M -836M -904M -2 985M -620M -1 978M -2 029M
freeCashFlow 8 612M 1 283M 414M -459M 63M 180M -3 152M -1 812M -204M 827M 4 600M 1 565M 5 388M 4 471M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-19 2024-02-21 2023-02-22 2022-02-23 2021-02-17
fiscalYear 2024 2023 2022 2021 2020
otherInvestingActivities -3 043M -2 532M -1 337M -644M 103M
netCashProvidedByInvestingActivities -9 302M -7 153M -3 763M -2 868M -2 259M
netDebtIssuance 8 901M 8 650M -62M 501M 292M
longTermNetDebtIssuance 10 753M 3 959M -1 560M 505M 1 786M
shortTermNetDebtIssuance -1 852M 4 691M 1 498M -4M -1 494M
netStockIssuance -2 500M -750M -1 500M -1 250M -500M
netCommonStockIssuance -2 500M -750M -1 500M -1 250M -500M
commonStockIssuance 0 0 0 0 0
netPreferredStockIssuance 0 0 0 0 0
netDividendsPaid -4 680M -4 069M -3 536M -3 087M -2 687M
commonDividendsPaid -4 680M -4 069M -3 536M -3 087M -2 687M
preferredDividendsPaid 0 0 0 0 0
otherFinancingActivities -491M -335M -309M -296M -242M
netCashProvidedByFinancingActivities 1 230M 3 496M -5 407M -4 131M -3 137M
incomeTaxesPaid 0 0 0 0 0
interestPaid 0 0 0 0 0

Earning call transcript

2025 q4
2026-02-04 ET (fiscal 2025 q4)
2025 q3
2025-10-30 ET (fiscal 2025 q3)
2025 q2
2025-08-07 ET (fiscal 2025 q2)
2025 q1
2025-05-01 ET (fiscal 2025 q1)
2024 q4
2025-02-06 ET (fiscal 2024 q4)
2024 q3
2024-10-30 ET (fiscal 2024 q3)
2024 q2
2024-08-08 ET (fiscal 2024 q2)
2024 q1
2024-04-30 ET (fiscal 2024 q1)
2023 q4
2024-02-06 ET (fiscal 2023 q4)
2023 q3
2023-11-02 ET (fiscal 2023 q3)
2023 q2
2023-08-08 ET (fiscal 2023 q2)
2023 q1
2023-04-27 ET (fiscal 2023 q1)
2022 q4
2023-02-02 ET (fiscal 2022 q4)
2022 q3
2022-11-01 ET (fiscal 2022 q3)
2022 q2
2022-08-04 ET (fiscal 2022 q2)
2022 q1
2022-04-28 ET (fiscal 2022 q1)

SEC forms

Show financial reports only

SEC form 8
2026-02-04 12:05 ET
Eli Lilly published news for 2025 q4
SEC form 8
2026-02-04 12:05 ET
Eli Lilly reported for 2025 q4
SEC form 10
2025-10-30 15:15 ET
Eli Lilly reported for 2025 q3
SEC form 8
2025-10-30 11:03 ET
Eli Lilly published news for 2025 q3
SEC form 8
2025-10-30 11:03 ET
Eli Lilly published news for 2025 q3
SEC form 10
2025-08-07 13:59 ET
Eli Lilly reported for 2025 q2
SEC form 8
2025-08-07 11:05 ET
Eli Lilly published news for 2025 q2
SEC form 8
2025-08-07 11:05 ET
Eli Lilly published news for 2025 q2
SEC form 10
2025-05-01 15:30 ET
Eli Lilly reported for 2025 q1
SEC form 8
2025-05-01 11:03 ET
Eli Lilly published news for 2025 q1
SEC form 8
2025-05-01 11:03 ET
Eli Lilly published news for 2025 q1
SEC form 10
2025-05-01 00:00 ET
Eli Lilly published news for 2025 q1
SEC form 10
2025-02-19 15:10 ET
Eli Lilly published news for 2024 q4
SEC form 10
2025-02-19 00:00 ET
Eli Lilly reported for 2024 q4
SEC form 8
2025-02-12 20:28 ET
Eli Lilly published news for 2024 q4
SEC form 8
2025-02-12 20:28 ET
Eli Lilly published news for 2024 q4
SEC form 8
2025-02-12 20:28 ET
Eli Lilly published news for 2024 q4
SEC form 8
2025-02-12 20:28 ET
Eli Lilly published news for 2024 q4
SEC form 8
2025-02-12 20:28 ET
Eli Lilly published news for 2024 q4
SEC form 8
2025-02-06 07:05 ET
Eli Lilly published news for 2024 q4
SEC form 8
2025-02-06 07:05 ET
Eli Lilly published news for 2024 q4
SEC form 8
2025-01-14 00:00 ET
Eli Lilly published news for 2024 q4
SEC form 8
2025-01-14 00:00 ET
Eli Lilly published news for 2024 q4
SEC form 10
2024-10-30 11:54 ET
Eli Lilly reported for 2024 q3
SEC form 8
2024-10-30 07:05 ET
Eli Lilly published news for 2024 q3
SEC form 8
2024-10-30 07:05 ET
Eli Lilly published news for 2024 q3
SEC form 10
2024-10-30 00:00 ET
Eli Lilly published news for 2024 q3
SEC form 10
2024-08-08 11:28 ET
Eli Lilly reported for 2024 q2
SEC form 8
2024-08-08 07:04 ET
Eli Lilly published news for 2024 q2
SEC form 8
2024-08-08 07:04 ET
Eli Lilly published news for 2024 q2
SEC form 10
2024-08-08 00:00 ET
Eli Lilly reported for 2024 q2
SEC form 10
2024-04-30 12:04 ET
Eli Lilly reported for 2024 q1
SEC form 8
2024-04-30 07:04 ET
Eli Lilly published news for 2024 q1
SEC form 8
2024-04-30 07:04 ET
Eli Lilly published news for 2024 q1
SEC form 10
2024-04-30 00:00 ET
Eli Lilly reported for 2024 q1
SEC form 10
2024-02-21 00:00 ET
Eli Lilly reported for 2023 q4
SEC form 8
2024-02-06 00:00 ET
Eli Lilly published news for 2023 q4
SEC form 8
2024-02-06 00:00 ET
Eli Lilly published news for 2023 q4
SEC form 10
2023-11-02 11:21 ET
Eli Lilly reported for 2023 q3
SEC form 8
2023-11-02 07:02 ET
Eli Lilly published news for 2023 q3
SEC form 10
2023-11-02 00:00 ET
Eli Lilly published news for 2023 q3
SEC form 10
2023-08-08 13:23 ET
Eli Lilly reported for 2023 q2
SEC form 6
2023-08-08 07:01 ET
Eli Lilly published news for 2023 q2
SEC form 10
2023-08-08 00:00 ET
Eli Lilly published news for 2023 q2
SEC form 8
2023-08-08 00:00 ET
Eli Lilly published news for 2023 q2
SEC form 6
2023-06-22 15:14 ET
Eli Lilly published news for 2023 q1
SEC form 10
2023-04-27 00:00 ET
Eli Lilly reported for 2023 q1
SEC form 8
2023-04-27 00:00 ET
Eli Lilly published news for 2023 q1
SEC form 6
2023-03-17 16:05 ET
Eli Lilly published news for 2022 q4
SEC form 6
2023-02-24 17:00 ET
Eli Lilly published news for 2022 q4
SEC form 10
2023-02-22 10:26 ET
Eli Lilly reported for 2022 q4
SEC form 10
2023-02-22 00:00 ET
Eli Lilly reported for 2022 q4
SEC form 6
2023-02-14 17:19 ET
Eli Lilly published news for 2022 q4
SEC form 6
2023-02-14 17:10 ET
Eli Lilly published news for 2022 q4
SEC form 6
2023-02-14 17:07 ET
Eli Lilly published news for 2022 q4
SEC form 6
2023-02-14 16:43 ET
Eli Lilly published news for 2022 q4
SEC form 6
2023-02-14 16:34 ET
Eli Lilly published news for 2022 q4
SEC form 6
2023-02-03 17:04 ET
Eli Lilly published news for 2022 q4
SEC form 6
2023-02-03 17:01 ET
Eli Lilly published news for 2022 q4
SEC form 6
2023-02-03 16:57 ET
Eli Lilly published news for 2022 q4
SEC form 6
2023-02-03 16:54 ET
Eli Lilly published news for 2022 q4
SEC form 6
2023-02-03 16:51 ET
Eli Lilly published news for 2022 q4
SEC form 6
2023-02-03 16:45 ET
Eli Lilly published news for 2022 q4
SEC form 6
2023-02-03 16:35 ET
Eli Lilly published news for 2022 q4
SEC form 6
2023-02-02 07:13 ET
Eli Lilly published news for 2022 q4
SEC form 8
2023-02-02 00:00 ET
Eli Lilly published news for 2022 q4
SEC form 6
2023-01-03 16:40 ET
Eli Lilly published news for 2022 q4
SEC form 6
2022-12-13 07:03 ET
Eli Lilly published news for 2022 q3
SEC form 8
2022-12-13 00:00 ET
Eli Lilly published news for 2022 q3
SEC form 6
2022-11-22 17:34 ET
Eli Lilly published news for 2022 q3
SEC form 6
2022-11-22 17:20 ET
Eli Lilly published news for 2022 q3
SEC form 6
2022-11-22 17:15 ET
Eli Lilly published news for 2022 q3
SEC form 6
2022-11-22 17:11 ET
Eli Lilly published news for 2022 q3
SEC form 6
2022-11-22 17:08 ET
Eli Lilly published news for 2022 q3
SEC form 10
2022-11-01 11:16 ET
Eli Lilly reported for 2022 q3
SEC form 6
2022-11-01 07:03 ET
Eli Lilly published news for 2022 q3
SEC form 10
2022-11-01 00:00 ET
Eli Lilly reported for 2022 q3
SEC form 8
2022-11-01 00:00 ET
Eli Lilly published news for 2022 q3
SEC form 6
2022-10-12 16:08 ET
Eli Lilly published news for 2022 q3
SEC form 6
2022-09-06 16:22 ET
Eli Lilly published news for 2022 q2
SEC form 10
2022-08-04 11:31 ET
Eli Lilly reported for 2022 q2
SEC form 6
2022-08-04 07:05 ET
Eli Lilly published news for 2022 q2
SEC form 10
2022-08-04 00:00 ET
Eli Lilly reported for 2022 q2
SEC form 8
2022-08-04 00:00 ET
Eli Lilly published news for 2022 q2
SEC form 6
2022-06-27 16:36 ET
Eli Lilly published news for 2022 q1
SEC form 6
2022-05-16 16:51 ET
Eli Lilly published news for 2022 q1
SEC form 6
2022-05-06 16:23 ET
Eli Lilly published news for 2022 q1
SEC form 6
2022-05-04 15:04 ET
Eli Lilly published news for 2022 q1
SEC form 10
2022-04-29 11:57 ET
Eli Lilly reported for 2022 q1
SEC form 10
2022-04-29 00:00 ET
Eli Lilly reported for 2022 q1
SEC form 6
2022-04-28 07:05 ET
Eli Lilly published news for 2022 q1
SEC form 8
2022-04-28 00:00 ET
Eli Lilly published news for 2022 q1
SEC form 6
2022-04-14 16:57 ET
Eli Lilly published news for 2022 q1
SEC form 8
2022-04-14 00:00 ET
Eli Lilly published news for 2022 q1
SEC form 6
2022-03-22 16:58 ET
Eli Lilly published news for 2021 q4
SEC form 6
2022-03-22 16:56 ET
Eli Lilly published news for 2021 q4
SEC form 6
2022-03-22 16:54 ET
Eli Lilly published news for 2021 q4
SEC form 6
2022-03-22 16:52 ET
Eli Lilly published news for 2021 q4
SEC form 6
2022-03-22 16:49 ET
Eli Lilly published news for 2021 q4
SEC form 6
2022-03-18 16:14 ET
Eli Lilly published news for 2021 q4
SEC form 6
2022-03-07 17:06 ET
Eli Lilly published news for 2021 q4
SEC form 6
2022-03-03 18:36 ET
Eli Lilly published news for 2021 q4
SEC form 6
2022-03-03 18:30 ET
Eli Lilly published news for 2021 q4
SEC form 6
2022-02-28 16:38 ET
Eli Lilly published news for 2021 q4
SEC form 6
2022-02-25 16:36 ET
Eli Lilly published news for 2021 q4
SEC form 10
2022-02-23 11:00 ET
Eli Lilly published news for 2021 q4
SEC form 10
2022-02-23 00:00 ET
Eli Lilly published news for 2021 q4
SEC form 6
2022-02-11 18:45 ET
Eli Lilly published news for 2021 q4
SEC form 6
2022-02-11 18:42 ET
Eli Lilly published news for 2021 q4
SEC form 6
2022-02-11 18:35 ET
Eli Lilly published news for 2021 q4
SEC form 6
2022-02-11 18:19 ET
Eli Lilly published news for 2021 q4
SEC form 6
2022-02-11 18:16 ET
Eli Lilly published news for 2021 q4
SEC form 6
2022-02-11 18:12 ET
Eli Lilly published news for 2021 q4
SEC form 6
2022-02-11 18:09 ET
Eli Lilly published news for 2021 q4
SEC form 6
2022-02-11 18:03 ET
Eli Lilly published news for 2021 q4
SEC form 6
2022-02-03 17:09 ET
Eli Lilly published news for 2021 q4
SEC form 6
2022-02-03 17:04 ET
Eli Lilly published news for 2021 q4
SEC form 6
2022-02-03 16:59 ET
Eli Lilly published news for 2021 q4
SEC form 6
2022-02-03 16:55 ET
Eli Lilly published news for 2021 q4
SEC form 6
2022-02-03 16:38 ET
Eli Lilly published news for 2021 q4
SEC form 6
2022-02-03 16:33 ET
Eli Lilly published news for 2021 q4
SEC form 6
2022-02-03 07:08 ET
Eli Lilly published news for 2021 q4
SEC form 8
2022-02-03 00:00 ET
Eli Lilly published news for 2021 q4
SEC form 6
2022-01-31 08:27 ET
Eli Lilly published news for 2021 q4
SEC form 6
2021-12-16 16:04 ET
Eli Lilly published news for 2021 q3
SEC form 6
2021-12-15 07:05 ET
Eli Lilly published news for 2021 q3
SEC form 8
2021-12-15 00:00 ET
Eli Lilly published news for 2021 q3
SEC form 6
2021-11-17 17:23 ET
Eli Lilly published news for 2021 q3
SEC form 6
2021-11-17 17:22 ET
Eli Lilly published news for 2021 q3
SEC form 6
2021-11-17 17:20 ET
Eli Lilly published news for 2021 q3
SEC form 6
2021-11-17 17:19 ET
Eli Lilly published news for 2021 q3
SEC form 6
2021-11-17 17:17 ET
Eli Lilly published news for 2021 q3
SEC form 6
2021-11-17 17:16 ET
Eli Lilly published news for 2021 q3
SEC form 6
2021-11-17 16:51 ET
Eli Lilly published news for 2021 q3
SEC form 6
2021-11-17 16:46 ET
Eli Lilly published news for 2021 q3
SEC form 6
2021-11-17 16:42 ET
Eli Lilly published news for 2021 q3
SEC form 10
2021-10-27 09:06 ET
Eli Lilly published news for 2021 q3
SEC form 10
2021-10-27 00:00 ET
Eli Lilly published news for 2021 q3
SEC form 6
2021-10-26 07:06 ET
Eli Lilly published news for 2021 q3
SEC form 8
2021-10-26 00:00 ET
Eli Lilly published news for 2021 q3
SEC form 6
2021-09-10 16:54 ET
Eli Lilly published news for 2021 q2
SEC form 6
2021-09-07 16:56 ET
Eli Lilly published news for 2021 q2
SEC form 6
2021-08-25 06:54 ET
Eli Lilly published news for 2021 q2
SEC form 6
2021-08-17 17:11 ET
Eli Lilly published news for 2021 q2
SEC form 6
2021-08-17 17:08 ET
Eli Lilly published news for 2021 q2
SEC form 6
2021-08-17 17:06 ET
Eli Lilly published news for 2021 q2
SEC form 6
2021-08-17 06:50 ET
Eli Lilly published news for 2021 q2
SEC form 10
2021-08-03 12:04 ET
Eli Lilly published news for 2021 q2
SEC form 6
2021-08-03 07:37 ET
Eli Lilly published news for 2021 q2
SEC form 10
2021-08-03 00:00 ET
Eli Lilly published news for 2021 q2
SEC form 8
2021-08-03 00:00 ET
Eli Lilly published news for 2021 q2
SEC form 6
2021-06-30 17:03 ET
Eli Lilly published news for 2021 q1
SEC form 6
2021-06-24 15:52 ET
Eli Lilly published news for 2021 q1
SEC form 6
2021-05-27 06:52 ET
Eli Lilly published news for 2021 q1
SEC form 6
2021-05-19 16:41 ET
Eli Lilly published news for 2021 q1
SEC form 6
2021-05-05 06:57 ET
Eli Lilly published news for 2021 q1
SEC form 10
2021-04-30 09:23 ET
Eli Lilly published news for 2021 q1
SEC form 10
2021-04-30 00:00 ET
Eli Lilly published news for 2021 q1
SEC form 6
2021-04-27 06:48 ET
Eli Lilly published news for 2021 q1
SEC form 8
2021-04-27 00:00 ET
Eli Lilly published news for 2021 q1
SEC form 6
2021-03-19 16:38 ET
Eli Lilly published news for 2020 q4
SEC form 6
2021-02-23 15:57 ET
Eli Lilly published news for 2020 q4
SEC form 6
2021-02-18 17:07 ET
Eli Lilly published news for 2020 q4
SEC form 10
2021-02-17 10:59 ET
Eli Lilly published news for 2020 q4
SEC form 6
2021-02-17 07:04 ET
Eli Lilly published news for 2020 q4
SEC form 6
2021-02-10 20:27 ET
Eli Lilly published news for 2020 q4
SEC form 6
2021-02-10 12:13 ET
Eli Lilly published news for 2020 q4
SEC form 6
2021-02-09 07:14 ET
Eli Lilly published news for 2020 q4
SEC form 6
2021-02-03 20:22 ET
Eli Lilly published news for 2020 q4
SEC form 6
2021-02-03 19:26 ET
Eli Lilly published news for 2020 q4
SEC form 6
2021-02-03 18:57 ET
Eli Lilly published news for 2020 q4
SEC form 6
2021-02-03 18:51 ET
Eli Lilly published news for 2020 q4
SEC form 6
2021-02-03 18:43 ET
Eli Lilly published news for 2020 q4
SEC form 6
2021-02-03 18:33 ET
Eli Lilly published news for 2020 q4
SEC form 6
2021-02-02 17:20 ET
Eli Lilly published news for 2020 q4
SEC form 6
2021-02-02 17:16 ET
Eli Lilly published news for 2020 q4
SEC form 6
2021-02-02 17:12 ET
Eli Lilly published news for 2020 q4
SEC form 6
2021-02-02 17:09 ET
Eli Lilly published news for 2020 q4
SEC form 6
2021-01-29 06:32 ET
Eli Lilly published news for 2020 q4
SEC form 6
2021-01-14 07:30 ET
Eli Lilly published news for 2020 q4
SEC form 6
2020-12-16 20:07 ET
Eli Lilly published news for 2020 q3
SEC form 6
2020-12-15 07:27 ET
Eli Lilly reported for 2020 q3
SEC form 6
2020-12-02 20:01 ET
Eli Lilly published news for 2020 q3
SEC form 6
2020-11-18 21:33 ET
Eli Lilly published news for 2020 q3
SEC form 6
2020-11-18 21:30 ET
Eli Lilly published news for 2020 q3
SEC form 6
2020-11-18 21:29 ET
Eli Lilly published news for 2020 q3
SEC form 6
2020-11-18 21:25 ET
Eli Lilly published news for 2020 q3
SEC form 6
2020-11-18 21:24 ET
Eli Lilly published news for 2020 q3
SEC form 6
2020-11-18 21:22 ET
Eli Lilly published news for 2020 q3
SEC form 6
2020-11-18 21:20 ET
Eli Lilly published news for 2020 q3
SEC form 10
2020-10-28 10:57 ET
Eli Lilly published news for 2020 q3
SEC form 6
2020-10-27 07:50 ET
Eli Lilly published news for 2020 q3
SEC form 6
2020-10-07 16:42 ET
Eli Lilly published news for 2020 q3
SEC form 6
2020-10-05 12:19 ET
Eli Lilly published news for 2020 q3